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OBJECTIVES: Despite available treatment options, chronic infection of individuals
with the hepatitis C virus (HCV), together with associated chronic liver diseases,
remains a significant public health burden in England and Wales. Fewer than half
of patients with genotype 1 chronic hepatitis C (CHC) achieve sustained virologic
response (SVR) following the current standard treatment with peginterferon alfa
and ribavirin. The aim of this analysis was to evaluate the cost-effectiveness of
boceprevir, a protease inhibitor, in combination with peginterferon alfa and riba-
virin, compared to peginterferon alfa and ribavirin alone, among treatment naïve
and previously treated patients with genotype 1 CHC in England and Wales.
METHODS: Specific treatment strategies for boceprevir have been outlined in the
UK licence for different patient groups. A Markov model was developed to evaluate
these treatment strategies for boceprevir triple-therapy compared to peginterferon
alfa and ribavirin alone, and to estimate the expected costs and health-related
quality of life benefits associated with them. The incremental cost-effectiveness of
including boceprevir in a new triple-therapy standard of care was assessed from
the perspective of the National Health Service and Personal Social Services over the
lifetime of the patient cohort. Clinical data inputs for each treatment strategy were
estimated based on subgroup analyses of the phase III trials for boceprevir.
RESULTS: The incremental cost-effectiveness ratio (ICER) for treatment-naïve pa-
tients was £11,601 when boceprevir triple-therapy was compared to current stan-
dard treatment with peginterferon alfa and ribavirin. For treatment-experienced
patients, the ICER with boceprevir triple-therapy was £2,909. These results were
robust to sensitivity analyses and below a threshold of £20,000. CONCLUSIONS:
The inclusion of boceprevir as part of a new triple-therapy standard of care for
patients with genotype 1 CHC is clinically efficacious and cost-effective, irrespec-
tive of whether patients have been previously treated. The use of boceprevir in this
setting is recommended by NICE.
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OBJECTIVES: Dual therapy with ribavirin and peg-interferon over a duration of
up to 72 weeks (W) has been the former standard of care in patients with chronic
Hepatitis C (HCV) genotype 1 and is still used in some patients. The aim of this
analysis is to evaluate the direct HCV-related costs and effects of dual therapy in
therapy-naïve and pretreated patients in Germany.METHODS: In this retrospec-
tive chart review study, dual therapy in patients with chronic HCV genotype 1 in
2008/2009 was evaluated in Germany. Data from patients treated with a combi-
nation of ribavirin and peg-interferon were retrospectively documented during
the treatment period and thereafter (on average 61 W of post-treatment follow-
up). A total of 208 therapy-naïve and 182 pretreated patients from 31 study sites
were included in the analysis. RESULTS: Mean time since first diagnosis of HCV
was 6.0 years and 10.4 years in therapy-naïve and pretreated patients, respec-
tively. 33.0% of pretreated patients were prior non responders, 37.9% were re-
lapsers. The average treatment duration during study was 42 W (SD 22W) both in
therapy-naïve and pretreated patients. Sustained virological response (SVR)
was demonstrated in 58.1% of therapy naïve and 36.6% of pretreated patients
with HCV-RNA measurements available (167 and 142 patients with measure-
ment, respectively). Mean per patient costs related to HCV during therapy from
the statutory health insurance perspective were 14,554€ (SD 9,139€) for therapy-
naïve and 14,590€ (SD 10,443€) for pretreated patients. Main cost-driver of treat-
ment was medication cost, accounting for 87% of total costs, followed by sick
leaves and diagnostics. Hospitalizations and physician visits played a less im-
portant role in terms of costs. CONCLUSIONS: Especially in pretreated patients,
HCV dual therapy is costly due to the low treatment success rate. This empha-
sizes the need for treatments with improved efficacy, minimizing costly non-
response resulting in potential cost savings.
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OBJECTIVES: To assess cost-effectiveness of adalimumab versus standard care
(SC) for treating patients with severely active Crohn’s disease (CD) in Germany
from a societal perspective. Additionally, cost-per-remitter for adalimumab was
estimated and compared with infliximab 5mg/kg maintenance therapy.
METHODS: To compare adalimumab to SC, a 4-disease-state clinical model (ie,
remission, moderate, severe, very severe) based on the Crohn’s Disease Activity
Index (CDAI) was constructed tracking patients over their lifetimes. The model
estimated direct costs, indirect costs, and quality-adjusted life-years (QALYs)
from the German societal perspective. Efficacy inputs for adalimumab were
based on actual observations from CHARM (Crohn’s Trial of the Fully Human
Antibody Adalimumab for Remission Maintenance). Using data from CLASSIC I
(Clinical Assessment of Adalimumab Safety and Efficacy Studied as Induction
Therapy in Crohn’s Disease), a regression model was used to predict efficacy of
SC. Direct/indirect costs and utility inputs were derived from public sources and
literature. To compare adalimumab to infliximab, cost-per-remitter was esti-
mated by dividing costs by the percentage of patients in remission on a yearly
basis. Remission rates of adalimumab and infliximab upon baseline matching
adjustment for patients with moderate-to-severe CD came from CHARM and
ACCENT I (A Crohn’s Disease Clinical Trial Evaluating Infliximab in a New Long-
Term Treatment Regimen), respectively. RESULTS: The incremental costs per
QALY gained for adalimumab versus SC were €37,270 (2012 Euro) over a lifetime
horizon in the base case. One-way sensitivity analyses varying key parameters
produced incremental costs per QALY gained ranging from €23,011–€51,528
when compared with SC. An average of 47.2% adalimumab-treated and 37.1%
infliximab-treated patients were in remission yearly. The corresponding cost-
per-remitter was €54,823 for adalimumab and €88,506 for infliximab.
CONCLUSIONS: Adalimumab appears to be cost-effective compared with SC for
treating patients with severely active CD. The cost-per-remitter for mainte-
nance therapy was less for adalimumab than for infliximab.
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OBJECTIVES: In patients with chronic infection with hepatitis C virus (HCV) geno-
type 1 who did not achieve a sustained response to the standard therapy with
peginterferon/ribavirin (PR) the combination of boceprevir (B) or telaprevir (T) plus
peginterferon alpha/ribavirin have shown to produce a higher rate of sustained
virologic response (SVR) than the retreatment with PR. The aim of this study is to
assess the cost effectiveness of these two (BPR and TPR) antiviral regimens.
METHODS: We developed a Markov model to describe the clinical history of previ-
ously treated HCV genotype 1 patients who did not achieve SVR in which one
cohort (1) receives PR for 4 weeks followed by BPR for 32 weeks and, those patients
with a detectable HCV RNA level at week 8 receive PR for an additional 12 weeks;
cohort 2 patients receive 12 weeks TPR followed by 36 weeks PR. All patients are
followed for their expected lifetime. The reference patient is 30-year-old with CHC
without cirrhosis. The SVRs to BPR and TPR cohorts came from RESPOND 2 and
REALIZE studies. Quality of life for each health state was based on literature. Costs
for each health state were based on three Delphi panels, one with hepatologists,
one with intensivists and another with oncologists. Costs in 2011 Brazilian Reais
and benefits were discounted at 3%. RESULTS: The combination BPR increases life
expectancy by 0.60 years and quality adjusted life years (QALY) by 0.89 years com-
pared to TPR. BPR is cheaper than TPR (-23,428 Brazilian Reais). CONCLUSIONS: In
Brazil, for the treatment of previously treated patients with HCV genotype 1 infec-
tion boceprevir plus peginterferon alpha/ribavirin is dominant compared with te-
laprevir plus peginterferon alpha/ribavirin.
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OBJECTIVES: The study compares the cost-effectiveness (CE) of dexlansoprazole
with other proton pump inhibitors (PPI) currently included in the Mexico National
Formulary (Positive List) for treatment of erosive esophagitis (EE). METHODS: A
decision tree with the 8-week temporal horizon was designed for patients over 18
with EE confirmed by endoscopy. The perspective taken is that of second-level
public health institutions. Treatment alternatives modelled are dexlansoprazole 60
mg/day, esomeprazole 40 mg/day; omeprazole 20 mg/day, pantoprazole 40mg/day,
rabeprazole 20 mg/day. Possible outcomes considered were healing or not healing,
the latter possibly leading to surgery. Costs included in the model were treatment
regimens, consult, endoscopy, surgery (when necessary), and hospitalization days
(when necessary) and were taken from official or published sources. Effectiveness
was measured in terms of percentage of patients with healed oesophagus. A
weighted average of effectiveness was calculated for use in the model. One-way
sensitivity analyses of cost and effectiveness variables and a Monte Carlo (MC)
simulation of a 1000 cohorts were also conducted to test the robustness of the
results. RESULTS: Compared to all PPIs modelled/tested, dexlansoprazole was
highly dominant, being more effective (0.9270) and less costly (USD$ 1.27 per day),
even when compared to omeprazole’s USD$ 0.015 per DDD. It was therefore not
considered necessary to calculate the Incremental Cost-Effectiveness Ratio (ICER)
since these would be negative. The sensitivity analyses and Monte Carlosimula-
tions found omeprazole to be the second-best alternative, and actually dominant
in 16.7% of the MC simulations. CONCLUSIONS: Dexlansoprazole was found to be
dominant compared to all PPIs evaluated for EE, being both more effective and less
costly for public institutions in Mexico.
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OBJECTIVES: Infliximab is indicated in Crohn’s disease (CD) resistant to standard
treatment (ST), but its impact on health care costs and quality-adjusted life-expec-
tancy is incompletely understood. We assessed the cost-effectiveness of episodic
(ET) and maintenance (MT) infliximab treatment in CD patients with 10-years
follow-up. METHODS: A total of 212 incident adult CD patients (age at onset
34.414.5 years, 49.4% male) were treated with antibiotics, mesalazine, corticoste-
roids, thiopurines, surgery (comprising ST) over 10-years to 2004. Eight health
states were defined by intensity of therapy in these patients. We determined
Markov transition probabilities between these states, health care costs and QALYs
in 3 month-cycles. This cohort was modeled to allow drug-refractory or pre-surgery
patients to receive infliximab: either ET in one cycle, or MT in responders for a
period of 1-year (MT-1yr) or for 10-years (MT-10 yrs). Transition probabilities of ST
were applied to patients getting IFX; the probability of continuing infliximab in MT
was set to correct for decay. Health care costs and QALYs in ET and MT were
estimated for 10-years (discounted at 3%) and compared with those of ST patients.
RESULTS: The average cost (QALYs gained) per patient over 10-years was €23,169
(6.7014) for ST; €21,691 (7.0403) for ET, €29,012 (7.0553) for MT-1yr, and €50,416
(7.2603) for MT-10 yrs. ST was associated with higher costs and lower outcomes and
was thus dominated by ET. The incremental cost-effectiveness ratios (ICERs) of
MT-1yr and MT-10 yrs over ST were €16,510/QALY gained, and €48,751/QALY
gained, respectively. When compared with ET, the ICERs of MT-1yr and MT-10 yrs
were €488,066/QALY gained, and €130,568/QALY gained, respectively. When the
infliximab price was halved these ICERs remained very high. CONCLUSIONS: ET or
MT with infliximab are either cost-saving or cost-effective when compared with
ST. However, at current drug prices, MT does not provide good value for money
when compared with ET.
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OBJECTIVES: To evaluate direct medical costs, health outcomes, and cost-effec-
tiveness of 48-week Peginterferon alpha-2a with 2nd line 2-years Entecavir
treatment versus 3 years Entecavir treatment for HBeAg-positive chronic hep-
atitis B according to the Response Guided Treatment (RGT) strategy in China.
METHODS: A Markov model was designed to evaluate the direct medical costs
and outcomes (life years and QALYs gained) of treating HBeAg-positive chronic
hepatitis B in China, with a maximum analysis time horizon of 80 years. The
model included 10 health states – Chronic hepatitis B (CHB), HBeAg seroconver-
sion, HBsAg loss, CHB with resistance, Compensated cirrhosis, Decompensated
cirrhosis, Hepatocellular carcinoma, Liver transplant, Post-liver transplant and
death. Based on the analysis of published literature, a two-round expert panel
survey was conducted among 22 hepatitis B specialists nationally to identify
clinical and utility data. From the perspective of China’s health insurance sys-
tem, cost data was calculated based on the published literature about CHB
economic burden. A discounting rate at 3% was used to discount medical costs
and health outcomes that happened at different years. A univariate sensitivity
analysis was performed to understand the key drivers and general sensitivity of
the model. RESULTS: The model results showed that the utilization of Peginter-
feron regimen can prolong1.80 QALYs (15.00 years vs. 13.20 years), compared to
the 3 years Entecavir treatment. The total cost per patient treated with Pegin-
terferon and Entecavir was RMB 163,638 yuan (US$ 25,568) and RMB 145,116
yuan (US$ 22,674), respectively. The discounted incremental cost per QALY
gained for Peginterferon regimen was RMB 10,298 yuan (US$ 1,609) (Exchange
rate: 1 US$  6.4 CNY). CONCLUSIONS: The results of the model suggest that
48-week Peginterferon alpha-2a with 2-years Entecavir treatment as 2nd line
improves health outcomes in a cost-effective manner compared with 3 years
Entecavir for the treatment of HBeAg-positive chronic hepatitis B in China.
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OBJECTIVES: To estimate the cost-effectiveness of telaprevir in combination
with peginterferon alpha and ribavirin (PR) compared to PR alone in previously
treated patients. METHODS: A cost-utility analysis based on previously pub-
lished Markov models for chronic hepatitis C was used. Efficacy in the model
was derived from results of randomized placebo controlled trial (REALIZE). RE-
ALIZE compared telaprevir in combination with PR to PR alone in patients who
failed previous treatment. The trial showed significantly higher response rates
in the telaprevir patient cohort. Utility values corresponding to each health
state in the model were obtained from a NICE Health technology Assessment
and were combined with data from REALIZE. Local cost data sources were from
published price lists, clinical guidelines, product labels and expert opinion (DEL-
PHI panel). The effectiveness was measured in quality-adjusted life years
(QALY). Time horizon was set at lifelong (100 years of age or till patient dies) and
a payers’ perspective was adopted. Discount rate was 5% per year for both costs
and effects according to actual Ministry of Health guidelines for health eco-
nomic evaluation. Both one-way and probabilistic sensitivity analyses were
performed. RESULTS: Incremental cost effectiveness ratio (ICER) for telaprevir
in combination with PR compared to PR alone was 14 209 €/1 QALY. Costs for one
life year saved (LYS) were 20 026 €/1 LYS. Model was most sensitive to price of
telaprevir in deterministic sensitivity analysis. In probabilistic sensitivity anal-
ysis 75 % of simulations were below 26 650 €/1 QALY. CONCLUSIONS: Telaprevir
in combination with PR is a cost-effective compared to PR alone for the treat-
ment of chronic hepatitis C in patient who failed previous treatment with PR in
a Slovakian health care system.
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OBJECTIVES: Linaclotide is a novel once daily, orally delivered peptide that acts on
all key IBS-C symptoms. The aim of this analysis was to estimate the daily cost that
would result in linaclotide being considered cost-effective in the UK, given differ-
ent levels of willingness–to-pay (WTP).METHODS:A within-trial analysis was used
to estimate the economically justifiable price from a payer perspective in the UK
using patient-level data from a 26-week Phase III, randomized, double-blind trial of
linaclotide 290g daily (n401) versus placebo (n403) in IBS-C patients (modified
Rome II criteria). EQ-5D data was collected at randomization and each subsequent
visit. The UK valuation of the EQ-5D was applied to the raw data to estimate the
utility for each patient. Missing data were interpolated using the last-observation-
carried-forward (LOCF) method. The WTP was varied from £15,000-£20,000/QALY.
The only cost considered was that of linaclotide; total cost of treatment was
weighted by compliance. Resource use was assumed to be equal between arms.
Bootstrapping was performed to account for uncertainty. A scenario analysis was
conducted using data from a 12-week linaclotide trial in a similar population.
RESULTS: Patients treated with linaclotide gained 0.016 QALYs over the 26-week
trial compared with patients in the placebo arm. At WTP thresholds of £15,000-
£20,000/QALY linaclotide could be cost-effective at a price of £1.30-£1.70. Over 75%
of the bootstrap estimates fell below a willingness-to-pay threshold of £20,000/
QALY. The method of addressing missing data had minimal impact on the ICER. In
the scenario analysis, the QALY gain for patients treated with linaclotide was even
greater, thus a price of £2.00-£2.65 may result in linaclotide being considered cost-
effective at thresholds of £15,000-£20,000/QALY. CONCLUSIONS: The base case
analysis showed linaclotide could be cost-effective at a price of up to £1.70/day in
the UK setting using conservative assumptions.
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OBJECTIVES: Irritable bowel syndrome with constipation (IBS-C) can decrease
work productivity and increase activity impairment, resulting in a substantial
economic burden for patients and employers. Linaclotide, a minimally-ab-
sorbed guanylate cyclase C agonist (GCCA), significantly improved abdominal
and bowel symptoms in 2 Phase 3 IBS-C trials. We evaluated the linaclotide
treatment effect on work productivity and activity impairment in IBS-C
patients. METHODS: In 2 Phase 3 trials, 1602 adults with IBS-C (modified Rome II
criteria) were randomized to oral linaclotide 290 g once daily or placebo. The
self-administered 6-item Work Productivity and Activity Impairment question-
naire for IBS-C (WPAI:IBS-C) was used to evaluate IBS-C symptom-related ab-
senteeism (work hours missed), presenteeism (degree symptoms affected work
productivity), overall work productivity loss (absenteeismpresenteeism) and
daily activity impairment (degree symptoms affected activities) over the previ-
ous week. Using pooled intent-to-treat data, changes in WPAI:IBS-C scores from
baseline to Weeks 4, 8, and 12 were assessed by analysis of covariance and
represented as percentages (higher percentagegreater productivity loss and
activity impairment). Absenteeism, presenteeism and work productivity as-
sessments included employed patients only. RESULTS: Compared to placebo,
linaclotide significantly reduced presenteeism, overall work productivity loss
and daily activity impairment, and numerically decreased absenteeism, at
Weeks 4, 8 and 12. Mean changes from baseline to Week-12 for linaclotide and
placebo, and the corresponding treatment effect (LS-means difference between
linaclotide and placebo, shown as “	”), respectively, were: presenteeism, -18.4%
and -13.1% (	-5.2, P0.0001); overall work productivity loss, -19.4% and -13.0%
(	-6.1, P0.0001); daily activity impairment, -19.9% and -15.2%(	-4.7,
P0.0001); absenteeism, -1.6% and -0.9% (	-0.5, P0.311). Assuming a 40-hour
work week, linaclotide reduced overall work productivity loss by 1.6-2.4
hours/week. CONCLUSIONS: Linaclotide significantly reduced presenteeism,
overall work productivity loss and daily activity impairment for IBS-C patients
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